Neuraminidase, Urease and Xanthine Oxidase Inhibitory Activities of Some Oxovanadium (IV) Complexes

Ertik O., Kaya B., Danışman Kalındemirtaş F., Kuruca D. S., Ülküseven B., Yanardağ R.

The 4th International Eurasian Conference on Biological and Chemical Sciences (EurasianBioChem 2021), Ankara, Türkiye, 24 - 26 Kasım 2021, ss.1142, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Ankara
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.1142
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Cancer is a disease that is caused by environmental and genetic factors, has a high mortality rate and the number of cases is increasing day by day. Therefore, new treatment approaches are very important and scientific studies are progressing in this direction. Enzyme inhibition is one of the treatment approaches because of the possible correlation between enzyme activity and cancer, and the activity of some enzymes is increased in cancer patients such as neuraminidase, urease and xanthine oxidase. Neuraminidase (NA) removes terminal sialic acids from gangliosides and is associated with tumorigenesis stages like regulation of growth factor receptor signaling. Many studies have showed that a relation between NA activity and cancer development in the literature. Urease enzyme is responsible of hydrolysis of urea to carbon dioxide and ammonia which in turn increased the pH and plays a key role in nitrogen metabolism. High urease activity is seen in many diseases such as cancer, peptic ulceration, and pyelonephritis. Xanthine oxidase (XO) catalyses the oxidation of hypoxanthine to xanthine and produces uric acid in purine catabolism and its activity can increase in some diseases such as cancer, type 2 diabetes, hypertension, hepatitis, inflammation. The current study was designed to investigate the effects of new synthesized oxovanadium (IV) complexes on activity of NA, urease and XO. All oxovanadium (IV) complexes had a good inhibitory activity of NA, urease and XO when compared with their positive control. IC50 values of oxovanadium (IV) complexes and quercetin were found in ranges 11.54–48.98 µg/mL for NA inhibition, oxovanadium (IV) complexes and thiourea were found in ranges 60.77–3434.02 µg/mL for urease inhibition, oxovanadium (IV) complexes and allopurinol were found in ranges 1.06–93.87 µg/mL for XO inhibition. These results showed that new synthesized oxovanadium (IV) complexes can be used in inhibition of NA, urease and XO.